Scientists need a better understanding of the chemistry of radium to be able to target the isotope radium-223 (Ra-223) to cancer cells. Once delivered, Ra-223 can destroy those cells with alpha ...

Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared ...

May 21, 2012 (Atlanta, Georgia) — In patients with bone metastases and castration-resistant prostate cancer (CRPC), radium-223 chloride (Ra-223) significantly prolonged overall survival and delayed ...

Source: Getty Images Radium-223, enzalutamide, and a bone-protecting agent may be a new treatment option for mCRPC patients with bone metastases, according to Silke Gillessen, MD. Radium-223 provided ...

Researchers at the University of Sheffield have received new funding to investigate if radium-223 (Ra-223), currently used to treat bone metastases in prostate cancer, might also help in bone spread ...

The administration of Pluvicto within six months of radium-223 treatment proved to be safe and efficacious in patients with metastatic castration-resistant prostate cancer, research showed. Patients ...

A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). This is an ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The addition of six cycles of radium-223 to first-line ...

Neal Shore, MD, is the National Urology Research Director for 21 st Century Oncology in Myrtle Beach, SC. He has been extensively involved in clinical trials of medications for treating prostate ...

The bone-targeting radioisotope radium-223 has delivered promising results in a randomised trial to test its efficacy in treatment of hormone-refractory prostate cancer (HRPC). The findings are ...